Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14410768 | 0.97 | ATM (0.35) | ATM | |
| SCHEMBL14410767 | 0.95 | ATM (0.34) | ATM | |
| SCHEMBL14410770 | 0.95 | ATM (0.34) | ATM | |
| SCHEMBL13676321 | 0.92 | ATM (0.38) | ATM | |
| SCHEMBL12562383 | 0.92 | ATM (0.38) | ATM | |
| SCHEMBL8235700 | 0.87 | ATM (0.33) | ATM | |
| SCHEMBL14410775 | 0.81 | ATM (0.31) | ATM | |
| SCHEMBL14410774 | 0.81 | ATM (0.31) | ATM | |
| SCHEMBL22928688 | 0.81 | ATM (0.35) | ATM | |
| SCHEMBL109494 | 0.81 | ATM (0.35) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240209004-A1 | BORIC ACID DERIVATIVE ACTING AS Beta-LACTAMASE INHIBITOR | TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240026028-A1 | ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240024498-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE, AND USE OF PHARMACEUTICAL COMPOSITION | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240024498-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE, AND USE OF PHARMACEUTICAL COMPOSITION | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230271969-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271969-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20150126550-A1 | PHARMACEUTICAL USES OF 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2015-05-07 | — | — | US | disclosed |
| US-20150005282-A1 | POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-01-01 | — | — | US | disclosed |
| US-8901140-B2 | 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-12-02 | — | — | US | disclosed |
| US-20140336207-A1 | PYRROLE SIX-MEMBERED HETEROARYL RING DERIVATIVE, PREPARATION METHOD THEREOF, AND MEDICINAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-11-13 | — | — | US | disclosed |
| US-8691822-B2 | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-04-08 | — | — | US | disclosed |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20130130997-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-20120165352-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209004-A1 | BORIC ACID DERIVATIVE ACTING AS Beta-LACTAMASE INHIBITOR | TREH, ME1, BCAT2 | ATM 3600/4885 |
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WEE1, CYP51A1, WEE2 | ATM 4036/4885 |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | GLP1R, GIPR, VIP | ATM 3674/4885 |
| US-20140336207-A1 | PYRROLE SIX-MEMBERED HETEROARYL RING DERIVATIVE, PREPARATION METHOD THEREOF, AND MEDICINAL USES THEREOF | JAK1, JAK3, JAK2 | ATM 3793/4885 |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | ATM 4514/4885 |
| US-20240024498-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE, AND USE OF PHARMACEUTICAL COMPOSITION | EPCAM, DSC1, FCGRT | ATM 2856/4885 |
| US-20240026028-A1 | ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF | ERBB3, EGFR, ERBB2 | ATM 3690/4885 |
| US-20230271969-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | NR5A1, WEE1, SHBG | ATM 2977/4885 |
| US-20130130997-A1 | C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, UGGT1 | ATM 4373/4885 |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | ATM 4026/4885 |
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | NOS1, NQO1, NOS2 | ATM 4161/4885 |
| US-20120165352-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | CSNK1G3, CSNK1A1, CSNK1A1L | ATM 579/4885 |
| US-20150005282-A1 | POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | GPR119, GPR55, GPR65 | ATM 3934/4885 |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | PLK2, PLK3, DMPK | ATM 1348/4885 |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | PARP1, PARP2, PARP4 | ATM 1013/4885 |
| US-20150126550-A1 | PHARMACEUTICAL USES OF 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES | PYGL, CSNK1G3, G6PD | ATM 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.